Table 1.
Demographics and clinical characteristics.
| Variables | No. (%) or median (interquartile range) | P-value | |
|---|---|---|---|
| Group | DDPC (6) | Conventional (9) | |
| Age, years | 48.2 (16–68) | 54.1 (36–63) | 0.25 |
| Male | 83.3% | 77.8% | 0.34 |
| BMIa | 27.2 (22.9–31.5) | 24.7 (20.1–30.2) | 0.41 |
| Etiology | 0.32 | ||
| CAD | 50% | 55.6% | |
| VHD | 50% | 11.1% | |
| AD | 0% | 22.2% | |
| CHD | 0% | 11.1% | |
| Complications | |||
| Hypertension | 55.6% | 33.3% | 0.23 |
| Diabetes mellitus | 44.4% | 33.3% | 0.54 |
| Smoking history | 55.6% | 66.7% | 0.54 |
| Femoral stenosis history | 22.2% | 16.7% | 0.34 |
| SOFA scores (when ALI was diagnosed) | 12.9 (12–14) | 12.7 (11–15) | 0.55 |
| Inotrope scores (when ALI was diagnosed) | 61.7 (43–78) | 54.4 (40–66) | 0.36 |
| ECMO Flow (LPM) (when ALI was diagnosed) | 3.5 (3.2–3.8) | 3.6 (3.5–3.9) | 0.92 |
BMI, body mass index; CAD, coronary artery disease; VHD, valvular heart disease; AD, aortic disease; CHD, congenital heart disease; SOFA, sequential organ failure assessment; Inotrope scores = dosage of dopamine (in μg/kg/min)+dosages of dobutamine (in μg/kg/min)+[dosages of epinephrine (in μg/kg/min+ norepinephrine (in μg/kg/min)] × 100+dosages of pituitrin (in u/min) × 100+dosages of milrinone (in μg/kg/min) × 15.